Syed Husain is a Nephrology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
622 W 168th St
New York, NY 100323720
Telephone
212-305-3273Provider last certified this registry record 2 Dec 2024.
Clinical trials
- Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension
Sponsor: University of Giessen
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20255 payments
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
44.4%Beta blocker22.6%Metoprolol Tartrate60%Carvedilol40%Part D<11 patientsAngiotensin receptor blocker (ARB)12.8%Losartan Potassium100%Part D<11 patients+ 1 more class in this area
Anti-infectives
21.1%Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor10.5%Entecavir100%Part D<11 patientsPenicillins with extended spectrum10.5%Amoxicillin100%Part D<11 patientsMetabolism & gastrointestinal
17.3%Proton pump inhibitor9%Pantoprazole Sodium100%Part D<11 patientsVitamin D3 Analog8.3%Calcitriol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2022–2025 per NIH RePORTER. The latest:
- Optimizing Deceased Donor Kidney Allocation Using Decision Science
New York University School of Medicine
FY2025$181,332K23DK133729 - Using Decision Making Science to Optimize Deceased Donor Kidney Allocation
Columbia University Health Sciences
FY2024$165,456K23DK133729 - Using Decision Making Science to Optimize Deceased Donor Kidney Allocation
Columbia University Health Sciences
FY2023$165,456K23DK133729
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”